Chariot Biosciences
Technology
Empowering Patients with Persistent Therapeutic Solutions
Chariot Bioscience has engineered Trypanosomal symbionts ("SimmbionsTM") which are implanted, via a single injection for sustained secretion of specific therapeutic proteins and peptides directly into the bloodstream, spleen, gut, and lymph nodes, eliminating the need for recurrent needle-based administration (and all the associated challenges of cold-chain logistics). Simmbions are designed to provide sustained release of medication in the patient for many months via a single injection.
If necessary, Simmbions can be reversed with antimicrobials - offering unprecedented control over disease management. Simmbion’s innovative cell therapy platform is designed to seamlessly integrate into patient lifestyles and marks a potential significant advancement in the management of chronic diseases.
The promise of chronic therapeutics are unrealized
Chariot Biosciences tackles three key challenges in chronic therapeutics.
Challenge One
Noncompliance is common
- Adherence to chronic meds is only 50%
- Lack of adherence drives 50% of treatment failures and 25% of hospitalizations
- $300 billion/year in healthcare costs could be curtailed by addressing adherence
Challenge Two
Repeated injections fail to deliver
a consistent therapy level
Current treatments using repeated injections cause drug levels in the body to rise and fall sharply, resulting in periods of high concentration that increase side effects, followed by dips where the treatment becomes less effective. Chariot Bio is developing a solution to keep drug levels steady within the ideal therapeutic range, aiming to enhance effectiveness and reduce side effects for patients.
Challenge Three
Reliance of cold chain logistics challenges supply chain
- Deviation from recommended temperature range can compromise effectiveness of the medication
- Rural hospitals can’t afford freezers
- Transportation at carefully controlled temperatures, where possible, is expensive and vulnerable to disruption
Chariot Biosciences holds great promise to reduce healthcare costs and significantly enhance the quality of life for those affected by chronic conditions which currently require therapeutics to be delivered by frequent injections.
Chariot — A living pharmacy via synthetic biology
The Chassis
Chariot identified a harmless South American commensal microbe (T. rangeli) with unique properties that make it an ideal chassis to precisely deliver therapeutics.
Trypanosome rangeli
The Engine
Chariot engineered genes code for a targeted therapeutic payload. These gene constructs are the 'Engine' that produces the therapeutic payload.
Plasmid Example: β-Glucocerebrosidase (GBA) gene
The SimmbionTM
Genes are loaded into the chassis where they utilize the cellular structures of the T. rengeli to produce the desired therapeutic. Simmbions implanted via a single injection express the targeted therapeutic over many months.
Simmbions are engineered to be implanted within a patient, via a single injection, and express the targeted therapeutic over many months.
Chariot Biosciences tackles three key challenges in chronic therapeutics.
Compliance
A single injection replaces need for frequent injections.
Consistent dose level
Simmbions provide constant low-level production and thereby avoids peaks and valleys of bolus dosing cased by frequent injections.
Cold chain requirements
A single injection of a Simmbion continually delivers therapy and avoids ongoing cold-chain requirements of the multiple injections that current biologics require.
Pending patents cover the Chassis, the Engine, the Simmbion, along with their uses.
Let's create a healthier future.
Together.
We’re excited to connect with those who share our passion for innovative healthcare solutions. Whether you have a question or want to learn more about Chariot Biosciences, we’d love to hear from you!
Get in Touch